|
|
||||||||

* Department of Pathology and Laboratory Medicine and
AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095
A large proportion of the CD8+ T cell pool in persons chronically infected with HIV consists of cells that show features of replicative senescence, an end stage characterized by irreversible cell cycle arrest, multiple genetic and functional changes, and shortened telomeres. The objective of our research was to determine whether constitutive expression of the gene for the human telomerase (hTERT) can prevent senescence-induced impairments in human virus-specific CD8+ T cells, particularly in the context of HIV-1 disease. Our results indicate that hTERT-expressing HIV-specific CD8+ lymphocytes show both an enhanced and sustained capacity to inhibit HIV-1 replication in in vitro coculture experiments, as well as prolonged ability to produce IFN-
and TNF-
in response to stimulation with HIV-1-derived peptides, as compared with vector-transduced controls. Loss of CD28 expression, the signature change of replicative senescence in cell culture, was retarded in those CD8+ T cell cultures that had high levels of CD28 at the time of hTERT transduction. These findings suggest that telomere shortening may be the primary driving force behind several aspects of CD8+ T cell dysfunction associated with replicative senescence. We also demonstrate reduced accumulation of the p16INK4a and p21WAF1 cell cycle inhibitors in hTERT-transduced lymphocytes, providing a possible mechanism by which stable hTERT expression is able to circumvent the senescence barrier in CD8+ T cells. Given the key role of CD8+ T cell function in controlling a variety of acute and latent viral infections, approaches to retard the functional decrements associated with replicative senescence may lead to novel types of immunotherapy.
Related articles in The JI:
This article has been cited by other articles:
![]() |
S. T. Parish, J. E. Wu, and R. B. Effros Modulation of T Lymphocyte Replicative Senescence via TNF-{alpha} Inhibition: Role of Caspase-3 J. Immunol., April 1, 2009; 182(7): 4237 - 4243. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Fauce, B. D. Jamieson, A. C. Chin, R. T. Mitsuyasu, S. T. Parish, H. L. Ng, C. M. Ramirez Kitchen, O. O. Yang, C. B. Harley, and R. B. Effros Telomerase-Based Pharmacologic Enhancement of Antiviral Function of Human CD8+ T Lymphocytes J. Immunol., November 15, 2008; 181(10): 7400 - 7406. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lichterfeld, D. Mou, T. D. H. Cung, K. L. Williams, M. T. Waring, J. Huang, F. Pereyra, A. Trocha, G. J. Freeman, E. S. Rosenberg, et al. Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors Blood, November 1, 2008; 112(9): 3679 - 3687. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Aubert and P. M. Lansdorp Telomeres and Aging Physiol Rev, April 1, 2008; 88(2): 557 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aviv, A. M Valdes, and T. D Spector Human telomere biology: pitfalls of moving from the laboratory to epidemiology Int. J. Epidemiol., December 1, 2006; 35(6): 1424 - 1429. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Menzel, M. Migliaccio, D. R. Goldstein, S. Dahoun, M. Delorenzi, and N. Rufer Mechanisms Regulating the Proliferative Potential of Human CD8+ T Lymphocytes Overexpressing Telomerase J. Immunol., September 15, 2006; 177(6): 3657 - 3668. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen and M. S. Goligorsky Premature senescence of endothelial cells: Methusaleh's dilemma Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1729 - H1739. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhou, X. Shen, J. Huang, R. J. Hodes, S. A. Rosenberg, and P. F. Robbins Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy J. Immunol., November 15, 2005; 175(10): 7046 - 7052. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |